KEY FEATURES
| Full Name | Forkhead Box Protein O3 |
|---|---|
| Synonym | FOX-O3; FOX2; FOXO3A; FKHRL1; FKHRL1P2; AF6q21 protein; Forkhead in rhabdomyosarcoma-like 1 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.15-10ng/mL |
| Sensitivity | 0.06ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human FOXO3 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human FOXO3. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human FOXO3 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human FOXO3, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human FOXO3. You can calculate the concentration of Human FOXO3 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human FOXO3 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.46 | 1.31 | 3.77 | 0.41 | 1.43 | 3.53 |
| Standard deviation | 0.02 | 0.06 | 0.12 | 0.02 | 0.07 | 0.18 |
| CV(%) | 5.17 | 4.24 | 3.13 | 5.58 | 4.77 | 5.13 |
RECOVERY
The recovery of Human FOXO3 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 86-101 | 93 |
| EDTA plasma (n=8) | 90-102 | 96 |
| Cell culture media (n=8) | 88-103 | 95 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human FOXO3 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with GAB2 ELISA Kits
| GRB2 ELISA Kit | publications with GAB2 and GRB2 |
| PTPN11 ELISA Kit | publications with GAB2 and PTPN11 |
| LYN ELISA Kit | publications with GAB2 and LYN |
| BCR ELISA Kit | publications with GAB2 and BCR |
| FYN ELISA Kit | publications with GAB2 and FYN |
| AKT1 ELISA Kit | publications with GAB2 and AKT1 |
| CRKL ELISA Kit | publications with GAB2 and CRKL |
| PIK3CB ELISA Kit | publications with GAB2 and PIK3CB |
Pathways associated with GAB2 ELISA Kit
| Axon Guidance Pathway | Axon Guidance Pathway |
| B Cell Receptor Signaling Pathway | B Cell Receptor Signaling Pathway |
| BDNF-TrkB Signaling Pathway | BDNF-TrkB Signaling Pathway |
| Chronic Myeloid Leukemia Pathway | Chronic Myeloid Leukemia Pathway |
| Cytokine Signaling In Immune System Pathway | Cytokine Signaling In Immune System Pathway |
| Developmental Biology Pathway | Developmental Biology Pathway |
| Disease Pathway | Disease Pathway |
| Diseases Of Signal Transduction Pathway | Diseases Of Signal Transduction Pathway |
| EGF/EGFR Signaling Pathway | EGF/EGFR Signaling Pathway |
Diseases associated with GAB2 ELISA Kit
| Nervous System Diseases | publications with GAB2 and Nervous System Diseases |
| Brain Diseases | publications with GAB2 and Brain Diseases |
| Hematologic Diseases | publications with GAB2 and Hematologic Diseases |
| Cell Transformation, Neoplastic | publications with GAB2 and Cell Transformation, Neoplastic |
| Neoplasm Metastasis | publications with GAB2 and Neoplasm Metastasis |
| Necrosis | publications with GAB2 and Necrosis |
| Neoplasm Invasiveness | publications with GAB2 and Neoplasm Invasiveness |
| Lung Neoplasms | publications with GAB2 and Lung Neoplasms |
| Neoplasms, Experimental | publications with GAB2 and Neoplasms, Experimental |
| Melanoma | publications with GAB2 and Melanoma |
Organs/Tissues associated with GAB2 ELISA Kit
| Blood | publications with GAB2 and Blood |
| Bone | publications with GAB2 and Bone |
| Brain | publications with GAB2 and Brain |
| Lung | publications with GAB2 and Lung |
| Muscle | publications with GAB2 and Muscle |
| Skin | publications with GAB2 and Skin |
| Lymph Node | publications with GAB2 and Lymph Node |
| Intestine | publications with GAB2 and Intestine |
| Eye | publications with GAB2 and Eye |
| Kidney | publications with GAB2 and Kidney |